An Atlantic profile examines how W. Bryan Hubbard became one of the most influential conservative advocates for psychedelic research, particularly ibogaine. The article traces his evolution from a lifelong Republican skeptical of psychedelics to a leading voice behind state-level research initiatives and the federal executive order accelerating psychedelic studies. It also explores how Hubbard has framed ibogaine as a bipartisan response to opioid addiction, trauma, and the unmet needs of veterans.
The piece balances Hubbard’s political and spiritual advocacy with the scientific uncertainty surrounding ibogaine. While early studies and patient accounts suggest potential benefits for opioid withdrawal, PTSD, and traumatic brain injury, researchers continue to emphasize the need for controlled clinical trials and careful attention to cardiac risks. The article ultimately considers whether growing Republican support can advance legitimate research without making psychedelic medicine overly partisan or undermining its scientific credibility.